Competition
Competition — Where Onyx Sits in the Pecking Order
Figures converted from INR at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.
Competitive Bottom Line
Onyx Biotec does not have a real moat. It holds a WHO-GMP licence to fill sterile ampoules and dry-powder vials in Solan, Himachal Pradesh — that is a licence to participate, not a competitive advantage. Inside the listed Indian sterile-CDMO ladder, Onyx is the smallest, lowest-margin, lowest-return player; its FY26 operating margin of 4.9% sits at roughly one-fifth of Caplin Point's 34.8% and one-fifth of Gland Pharma's 25.4%, and its $7M revenue is less than 2% of either. The single competitor that matters most is Akums Drugs & Pharmaceuticals — simultaneously the largest Indian CDMO (~30% domestic market share by value), a Tracxn-named direct competitor, and a customer that loan-licenses certain dosage forms to Onyx; that one relationship can compress or expand Onyx's volume base at Akums' discretion. The competitive picture is fragile, not broken: the business survives because it is too small to be worth Gland's or Caplin's attention, not because anything about its position is defended.
The Right Peer Set
The five peers below are the only listed Indian comparables that share Onyx's economic substitute set: B2B contract manufacturers of sterile injectables, dry-powder injections, or formulations sold to large pharma corporates. Two — JBCHEPHARM and COHANCE (the post-merger successor to RHP-named Suven Pharmaceuticals) — anchor to Onyx's own prospectus peer-comparison table. GLAND is the cleanest pure-play sterile-injectables substitute. CAPLIPOINT is the focused-mid-cap injectables exporter that demonstrates what a Caplin-shaped upgrade path could look like. AKUMS is Onyx's Tracxn-ranked #1 CDMO competitor and the broadest-dosage-form CDMO platform in the listed Indian set. Branded-pharma giants (Sun, Cipla, Lupin, Mankind) were rejected because they own brands and prescription pull rather than competing for CDMO conversion contracts; Brooks Laboratories, Themis Medicare and similar micro-caps were rejected as economically less direct substitutes.
The peer map says three things plainly. First, scale and operating margin are not the same thing: Caplin Point ($233M sales, 35% OPM) earns higher margins than Gland ($686M, 25%) and far higher than Akums ($465M, 12%), because focused sterile-injectables export economics beat diversified CDMO economics. Second, JB Chemicals is mis-categorised by P/E at 47.6x — the market is paying for branded-formulations 87% of its revenue, not for the 13% CDMO segment; comparing Onyx's nonexistent P/E to JB's is meaningless. Third, Onyx is not on the same chart at any visible resolution: its bubble is invisible against any of the peers, which is the most honest summary of its current competitive standing.
Where The Company Wins
Onyx has four narrow, real advantages over the peer set. None of them are moats; they are reasons the business survives in the long tail rather than reasons it ought to be valued like Caplin.
The cash conversion cycle chart is the cleanest "where Onyx wins" picture in the file: at 119 days, Onyx's CCC is shorter than Gland (255), Caplin (194), Cohance (159), and JB Chemicals (109 — the only peer that beats it). The cost of carrying that CCC at $7M revenue is small in absolute dollars. The same chart, however, says debtor days at 144 are the worst in the peer set after Caplin — Onyx wins on aggregate working capital only because it carries less inventory, not because it has bargaining power. Place the wins in context: this is a small, lightly-levered, niche-position business, not a defended franchise.
Where Competitors Are Better
The competitors are better than Onyx on every dimension that matters for long-term value creation. The list below is not a generic "they're bigger" complaint — it names specifically which peer wins on which axis and why.
The heatmap is the most damning chart in this file: every other peer either held their margin or expanded it over the FY22-FY26 window. Caplin compounded from 31% to 35%, Gland reset down from 34% to 25% but stabilised at the higher tier, JB Chemicals expanded from 24% to 27%, and even Akums lifted out of its FY22 loss to 12%. Only Onyx broke the wrong way — from a respectable 17% to 5% in a single year. That fact, on its own, is the cleanest possible summary of competitive disadvantage.
A specific dimension worth naming: Caplin Point is the upgrade-path comparable. Caplin earned 24-31% OPM at $25-130M revenue between FY15 and FY21, then compounded that into 33-35% at $180-235M by focusing relentlessly on LatAm injectables exports, building Caplin Steriles as a USFDA-approved sister facility, and refusing to dilute focus into commodity formulations. If Onyx ever earns Caplin-shaped economics, it will be because management makes a similarly hard product-mix bet over a similarly long horizon — not because growth comes faster.
Threat Map
The threat map skews toward "High" because Onyx's competitive position is structurally fragile rather than transitorily weak. The four high-severity threats — Akums loan-licensing withdrawal, working-capital squeeze (already live), single-site audit risk, and tier-1 anchor-customer loss — are all reversible-revenue events. The two most realistic near-term scenarios that would mark this stock down further are (a) Akums announcing internalisation of cephalosporin volumes during a quarterly call, and (b) any pharma buyer (Sun, Mankind, Aristo) publicly listing an alternative sterile CDMO partner for the same SKUs.
Moat Watchpoints
The single signal that decides this name. If you only read one disclosure from Onyx in FY27, make it the H1FY27 operating margin. A return to or above the FY25 14-17% band would confirm Unit II's fixed-cost stack is finally being absorbed; another half year near 3-7% would mean FY26 was not a ramp issue but the new normal — and at that point the competitive disadvantages catalogued above stop being theoretical and start eating book value.
Second-order signals worth tracking quarterly. Akums quarterly concall commentary on dosage-form expansion (does Akums internalise cephalosporin DPI?). Caplin Point's new general-injectables line completion (does it redeploy capacity to India domestic?). Any Sun Pharma or Mankind public disclosure of new CDMO partners for sterile injectables. Schedule M enforcement updates from CDSCO (does sub-scale competitor exit accelerate?).